Below are current clinical trials.7 studies in Amyotrophic lateral sclerosis
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to evaluate the effect of retigabine dosages on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS).
The purpose of this study is to evaluate the potential to use TMS as a way of functionally assessing target engagement in an efficacy study of Perampanel as a treatment for ALS. The study will also determine if there is a correlation between Perampanel dose and TMS MT.
This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and pharmacokinetic (PK) properties of GDC-0134. It will include two components: a Single-Ascending-Dose (SAD) stage and a Multiple-Ascending-Dose (MAD) stage.
The goals of this study are to identify biomarkers that allow improved staging or prognosis of the disease, and through the discovery of previously unrecognized immune abnormalities in ALS we aim to eventually identify immune therapies that may provide benefit in ALS.
This study is intended to obtain clinical information and establish a repository of DNA, RNA, peripheral blood monocyte, lymphocyte and skin tissue samples from people with ALS and related neurodegenerative motor neuron diseases, people with a family history of these conditions, and healthy people with no family history of these disorders. The samples will be used in future research to learn about how these disorders affect people, what causes these conditions, and how the investigators can tell when someone has this kind of disease. Future research may also include the generation of stem cells from stored blood cell and skin cell samples. Participants will not be paid for taking part in this study.
The purpose of this study is so that blood (plasma and blood cells) and/or extra spinal fluid (which was taken for clinical purposes) can be obtained and stored for later research on a large cohort of patients with progressive motor neuronopathies and neuropathies, many of which will be determined to suffer from Amyotrophic Lateral Sclerosis (ALS).
The purpose of this study is to collect and study blood samples that can be used in current and future research studies to identify genetic risk factors in ALS and identify potential biomarkers in blood collected in ALS patients. Biomarkers are non-genetic elements in your blood that may help us diagnose and monitor ALS more easily. There are no readily available sources of longitudinal DNA, RNA, monocytes, serum or plasma from people with ALS, ALS-FTD or similar neurodegenerative disorders or their family members for use in the identification of potential changes in gene structure over time or biomarkers in ALS. Future research will examine genes associated with the risk of ALS and potential biomarkers in blood collected over time to see if they change over time and can be used to diagnose and monitor people with ALS. This information is important for development of new medications for the treatment of ALS.
May 12, 2017
- Amyotrophic lateral sclerosis (ALS) fact sheet. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/amyotrophiclateralsclerosis/ALS.htm. Accessed July 12, 2016.
- Elman LB. Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease. http://www.uptodate.com/home. Accessed July 12, 2016.
- Maragakis NJ. Epidemiology and pathogenesis of amyotrophic lateral sclerosis. http://www.uptodate.com/home. Accessed July 12, 2016.
- McCluskey L. Familial amyotrophic lateral sclerosis. http://www.uptodate.com/home. Accessed July 12, 2016.
- Ingre C, et al. Risk factors for amyotrophic lateral sclerosis. Clinical Epidemiology. 2015;7:181.
- Crum BA (expert opinion). Mayo Clinic, Rochester, Minn. July 25, 2016.
- Galvez-Jimenez N. Symptom-based management of amyotrophic lateral sclerosis. http://www.uptodate.com/home. Accessed July 12, 2016.
- Elman LB, et al. Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease. http://www.uptodate.com/home. Accessed July 12, 2016.
- Miller RG, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227.
- Neurological diagnostic tests and procedures. National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/misc/diagnostic_tests.htm. Accessed July 12, 2016.
- Choudry RB, et al. Disease modifying treatment of amyotrophic lateral sclerosis. http://www.uptodate.com/home. Accessed July 12, 2016.
- ALS Association chapter support groups. The ALS Association. , http://www.alsa.org/community/support-groups/. Accessed July 12, 2016.
- Services in your community. The ALS Association. http://www.alsa.org/community/certified-centers/. Accessed July 12, 2016.
- Riggin ER. Allscripts EPSi. Mayo Clinic, Rochester, Minn. May 10, 2016.
- FDA approves drug to treat ALS. FDA. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm557102.htm. Accessed May 5, 2017.
Amyotrophic lateral sclerosis